2016, Number 5
PDF size: 327.60 Kb.
ABSTRACTThe consumption of marijuana extracted from Cannabis sativa and indica plants involves an important cultural impact in Mexico. Their psychological stimulatory effect is widely recognized; their biochemical and molecular components interact with CB1 and CB2 (endocannabinoid system) receptors in various central nervous system structures (CNS) and immune cells. The psychoactive element Δ-9-tetrahydrocannabinol (THC) can be reproduced synthetically.
Systematic reviews show evidence of therapeutic effectiveness of therapeutic marijuana only for certain symptoms of multiple sclerosis (spasticity, spasms and pain), despite attempts for its widespread use, including refractory childhood epilepsy. Evidence indicates significant adverse effects of smoked marijuana on the structure, functioning and brain connectivity. Cannabis exposure during pregnancy affects fetal brain development, potentially leading to later behavioral problems in children. Neuropsychological tests and advanced imaging techniques show involvement in the learning process in adolescents with substance use. Also, marijuana increases the cognitive impairment in patients with multiple sclerosis.
Social and ethical consequences to legally free marijuana for recreational use may be deleterious transcendentally. The medicinal or psychoactive cannabinol no addictive effect requires controlled proven efficacy and safety before regulatory approval studies.
Meyer J. La Cristiada, La guerra de los cristeros, México DF, Siglo XXI Editores, Primera edición, 1973.
Barrera R. Salvador Novo: Navaja de la Inteligencia. México, DF. Plaza y Valdés, S.A. de C.V., 1999.
Martín del Campo SL. Los efectos de las drogas: de sueños y pesadillas. México: Editorial Trillas, 2014.
Jones RT. Human effects: an overview. En Peterson RC, editor. Marijuana Research Findings: 1980. Rockville MD. National Institute on Drug Abuse: 1980:54-80.
Medical Marijuana and other Cannabinoides. Texas Physicians & Physician Assistants 2016; Vol. 141(4): 2-23.
Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008;184:435-477.
Skopp G, Richter B, Pőtsch L. Serum cannabinoid levels 24-48 hours after cannabis smoking. Arch Kriminol 2003;212(3-4):83-95.
Koppel BS, Brust JC, Fife T., et al. Systematic review: efficacy of medical marijuana in selected neurological disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82: 1556-1563.
Whiting PF, Wolf RF, Deshpande S, et al. Cannabinoids for Medical Use. A Systematic Review and Meta-analysis. JAMA 2015; 313(24):2456-2473.
Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. A Clinical Review. JAMA 2015; 313(24):2474-2483.
Wade DT, Makeda P, Robeson P, et al. Do cannabisbased medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A doubleblind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441.
Filloux FM. Can medical marijuana help pediatric patients? Neurology Reviews 2014;22(12):1-3.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. DSM-5. Washington D.C. American Psychiatry Association 2013.
Brauser D. Cannabis-Related ED Visits Rise in States with Legalized Used. Medscape Neurology, December 16, 2014:1-2.
Foti DJ, Kotov R, Guey LT, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. Aug 2010;167 (8):987-993.
Proal AC, Fleming J, Galvez-Buccollini JA, et al. A controlled family study of cannabis users with and without psychosis. Schizophr Res 2014;152:283-288.
French L, Gray C, Leonard G, et al. Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence. JAMA Psychiatry 2015;72(10):1002-1011.
Wu CS, Jew CP, Lu HC, et al. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurology 2014;6(4):459-480.
Dag NL, Leech SL, Goldsschmidt L, et al. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicology and Teratology 2011;33(1): 129-136.
Rose DZ, Guerrero WR, Mokin MV et al. Hemorrhagic stroke following use of synthetic marijuana “spice”. Neurology, August 28, 2015; vol 85 (13):1177-1179.
Wolff V, Armspach JP, Laver V, et al. Cannabis-related stroke. Myth or Reality?. Stroke 2013;44:558-563.
Valle L, Sebastián J, Rojas Jimenez S. Cannabinoides: un obstáculo cognitivo para conducir con seguridad. Acta Toxicológica Argentina 2014; 22(1): 23-32.
Ramae K, Berghaws G, van Laar M, et al. Doserelated risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004ñ 73(2):109-119.
Paggliaccio D, Barch DM, Bagdan R, et al. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 2015;72(10):994-1001.
Fibley FM, Asian S, Calhoun VD, et al. Longterm effects of marijuana use on the brain. PNAS 2014;11(47):16913-16915.
Mena I, Dőrr A, Viani S, et al. Efectos del consumo de marihuana en escolares sobre funciones cerebrales demostradas mediante pruebas neuropsicológicas e imágenes de neuro-SPECT. Salud Mental 2013; 36: 367-374.
Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I: frequency, patterns, and prediction. Neurology 1991;41:685-691.
Pryce G, Ahmed Z, Hankey DJ, et al. Cannabionids inhibit neurodegeneration in models of multiple sclerosis. Brain 2001;126:2191-2002.
Pryce G, Baker D. Cannabinoids Fail to Show Evidence of Slowing Down the Progression of Multiple Sclerosis, Evid Based Med 2015;20(4):124.
Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of cannabis on cognition in patients with MS. A psychometric and MRI study. Neurology 2014;82: 1879-1887.